SCHEMBL5853799

SCHEMBL5853799

Cc1ccc(C(=O)N[C@H](CN2CCN(Cc3ccc(Cl)cc3)CC2)C(C)C)cc1

nearest known ligand 0.63

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
CCR3 P51677 6/20 0.63
CCR1 P32246 2/20 0.50
HDAC6 Q9UBN7 2/20 0.49
CCR2 P41597 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.47
POLB P06746 1/20 0.47
ATM Q13315 1/20 0.47
HDAC1 Q13547 3/20 0.47
HDAC4 P56524 2/20 0.47
KCNH2 Q12809 1/20 0.47
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
HDAC8 Q9BY41 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5743617 1.00 CCR3 (0.63) CCR3CCR1HDAC6CCR2SMN1; SMN2
SCHEMBL5743620 1.00 CCR3 (0.63) CCR3CCR1HDAC6CCR2SMN1; SMN2
SCHEMBL5854299 0.89 CCR3 (0.75) CCR3HDAC6SMN1; SMN2ATMHDAC1
SCHEMBL5740928 0.89 CCR3 (0.75) CCR3HDAC6SMN1; SMN2ATMHDAC1
SCHEMBL5743078 0.89 CCR3 (0.64) CCR3HDAC6SMN1; SMN2ATMHDAC1
SCHEMBL5743086 0.89 CCR3 (0.64) CCR3HDAC6SMN1; SMN2ATMHDAC1
Hydrochloric Acid SCHEMBL3936111 0.88 CCR3 (0.74) CCR3HDAC6SMN1; SMN2ATMHDAC1
Hydrochloric Acid SCHEMBL3936105 0.88 CCR3 (0.74) CCR3HDAC6SMN1; SMN2ATMHDAC1
Hydrochloric Acid SCHEMBL6734198 0.88 CCR3 (0.74) CCR3HDAC6SMN1; SMN2ATMHDAC1
Hydrochloric Acid SCHEMBL6734201 0.88 CCR3 (0.74) CCR3HDAC6SMN1; SMN2ATMHDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6984637-B2 Cyclic amine derivatives-CCR-3 receptor antagonists SYNTEX (U.S.A.) LLC (US) 2006-01-10 US disclosed
US-20040266782-A1 Cyclic amine derivatives-CCR-3 receptor antagonists GONG LEYI (US) 2004-12-30 US disclosed
US-6770650-B2 CHEMOKINE RECEPTOR (CCR) ANTAGONISTS SUCH AS N-(1(S)-(4-(3,4-DICHLOROBENZYL)PIPERAZIN-1-YLMETHYL)-2-METHYLPROPYL)-4 -METHYLBENZAMIDE DIHYDROCHLORIDE SALT FOR TREATMENT OF ASTHMA SYNTEX (U.S.A.) LLC 2004-08-03 US disclosed
US-6683074-B1 PYRROLIDINYL, PIPERAZINYL AND AZEPINYL DERIVATIVES; INFLAMMATORY OR ALLERGIC DISEASES SYNTEX (U.S.A.) LLC 2004-01-27 US disclosed
US-20030153577-A1 Cyclic amine derivatives-CCR-3 receptor antagonists ROCHE BIOSCIENCE 2003-08-14 US disclosed
US-6339087-B1 FOR THERAPY OF INFLAMMATORY OR ALLERGIC DISEASES ARE SELECTED FROM ASTHMA, ALLERGIC RHINITIS, HYPERSENSITIVITY LUNG DISEASES, HYPERSENSITIVITY PNEUMONITIS, EOSINOPHILIC PNEUMONIAS, INFLAMMATORY BOWEL DISEASES, PSORIASIS, DERMATITIS SYNTEX (U.S.A.) LLC 2002-01-15 US disclosed
US-6323223-B1 CCR-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, METHODS FOR THEIR USE AND METHODS FOR PREPARING THESE COMPOUNDS. SYNTEX (U.S.A.) LLC 2001-11-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040266782-A1 Cyclic amine derivatives-CCR-3 receptor antagonists CCR3, CCR1, CCRL2 CCR3 1/4885CCR1 2/4885HDAC6 784/4885
US-20030153577-A1 Cyclic amine derivatives-CCR-3 receptor antagonists CCR3, CCR1, CCRL2 CCR3 1/4885CCR1 2/4885HDAC6 784/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.